| Autor: |
Hyung Joon Yim, Young Kul Jung, Sang Hoon Ahn, Won Kim, Jin Mo Yang, Jae Young Jang, Yong Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Joo Hyun Sohn, Jin Woo Lee, Sung Jae Park, Sun Young Yim, Jin Kyung Park, Soon Ho Um |
| Rok vydání: |
2023 |
| Popis: |
Background/aims No information is available regarding the influence of besifovir (BSV) on the occurrence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed to assess the reduced risk of HCC in patients undergoing BSV treatment. Methods Overall, 188 patients with CHB were treated with BSV for up to 8 years. We assessed the incidence of HCC during follow-up and compared it with the predictive numbers of HCC using models developed from untreated CHB patients. Additionally, we compared the performance of various HCC prediction models developed for patients with CHB receiving antiviral therapy. Results During the follow-up period of 8 years, five patients developed HCC; one of 139 patients with non-cirrhotic CHB, and four of 49 patients with liver cirrhosis. We compared the HCC incidence in non-cirrhotic patients with the predicted number derived from the REACH-B model. The standardized incidence ratio (SIR) was 0.128 (P = 0.039) at 7 years, suggesting a significant decrease in HCC incidence in non-cirrhotic CHB patients. The incidence of HCC in patients with cirrhosis was compared using the GAG-HCC model, and the SIR was 0.371 (P = 0.047) at 7.5 years, suggesting a significantly decreased HCC incidence. When we compared several HCC prediction models developed for CHB patients under antiviral therapy, the HCC-RESCUE model showed the highest area under the curve (0.924). Conclusions BSV decreases the risk of HCC in patients with CHB, with or without liver cirrhosis. HCC prediction was available for BSV-treated patients using the existing prediction models. Clinical trial registry website and trial number: ClinicalTrials.gov no: NCT01937806. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
